Balanced news tone
News Sentiment
KRRO sentiment intelligence
Korro Bio, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
49 relevant articles
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
+4.0% over one week, +25.4% over four weeks, trend active, and below fair value.
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
83/100 classification
One-week reaction
4.0%
Price confirming higher
Trend fit
Trend active
25.4% over four weeks
Fair value
-54.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
12
Neutral
33
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investing.com
Direct company coverage
Korro Bio CEO Ram Aiyar sells $196,672 in company stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Investing.com
GlobeNewswire
Direct company coverage
Korro to Present at the 2026 Jefferies Global Healthcare Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 11:00
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 11:00
- Source
- GlobeNewswire
MT Newswires
Direct company coverage
Citigroup Initiates Korro Bio at Buy With $21 Price Target
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 18 May 2026 11:39
- Source
- MT Newswires
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Stock Titan
Direct company coverage
Investors pour $85M into RNA editor Korro Bio’s genetic disease drugs
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Mar 2026 07:00
- Source
- Stock Titan
citybiz
Direct company coverage
Korro Announces $85 Million Private Placement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Mar 2026 07:00
- Source
- citybiz
Market source
Direct company coverage
We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Feb 2026 08:00
- Source
- Market source
Genetic Engineering and Biotechnology News
Direct company coverage
StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Nov 2025 08:00
- Source
- Genetic Engineering and Biotechnology News
BioSpace
Direct company coverage
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 13 Nov 2025 08:00
- Source
- BioSpace
Zacks Investment Research
Direct company coverage
Should I buy Korro Bio, Inc. (KRRO)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Apr 2024 01:06
- Source
- Zacks Investment Research
Stocktwits
Direct company coverage
Korro Bio Inc (KRRO) News, Articles, Events & Latest Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Nov 2023 02:32
- Source
- Stocktwits